Respiratory diseases remain one of the world’s biggest healthcare challenges, placing enormous pressure on healthcare systems while affecting millions of patients who often face delayed or difficult diagnoses. Traditional diagnostic methods can be time consuming, require specialist equipment and trained clinicians, and are not always easily accessible in primary care settings. As healthcare providers seek faster, more accurate, and more scalable diagnostic solutions, artificial intelligence is beginning to transform respiratory medicine. Cambridge based healthtech company TidalSense is at the forefront of this shift, and it has now secured fresh funding to expand its AI powered diagnostic technology across the United Kingdom, Europe, and the United States.
TidalSense has raised $19 million in a new funding round backed by new and existing investors, bringing the company’s total funding to approximately $40 million, including grant funding.
The investment will support wider deployment of its respiratory diagnostic platform, strengthen commercial operations, and accelerate international expansion.
The company aims to make respiratory testing faster, more accessible, and easier to deliver across healthcare systems.
Reinventing COPD Diagnosis
Founded in 2013, TidalSense is focused on improving the diagnosis of respiratory diseases, beginning with chronic obstructive pulmonary disease, commonly known as COPD.
COPD is one of the leading causes of illness and death worldwide, yet diagnosis often depends on spirometry, a test that has changed little over many decades.
Traditional spirometry requires specialist equipment, trained operators, and significant testing time, creating barriers for many healthcare providers and patients.
TidalSense has developed an alternative approach that combines advanced sensing technology with artificial intelligence to simplify the diagnostic process.
The company believes earlier diagnosis can lead to faster treatment and improved patient outcomes while reducing pressure on healthcare systems.
AI Powered Respiratory Testing
At the centre of TidalSense’s platform is N Tidal Diagnose, an AI powered diagnostic system that requires patients to breathe normally into a handheld device for just 75 seconds.
The device captures carbon dioxide waveforms, known as capnograms, which are then analysed using artificial intelligence models trained on more than 2.5 million patient breaths.
Instead of relying on forceful breathing manoeuvres required by conventional tests, the technology evaluates natural breathing patterns to identify signs of respiratory disease.
According to the company, the entire assessment can typically be completed in less than five minutes, allowing clinicians to examine significantly more patients during each clinic session.
Improving Access to Respiratory Care
One of the key advantages of the platform is its simplicity.
Healthcare professionals can learn to operate the device with minimal training, making it suitable for use across a wide range of clinical settings.
The technology has been designed to support primary care, community healthcare, and other environments where specialist respiratory expertise may not always be available.
By reducing both testing time and operational complexity, TidalSense aims to improve access to respiratory diagnosis while helping healthcare providers identify patients earlier in the course of disease.
The company believes this approach can help reduce inequalities in access to respiratory care while supporting more efficient clinical services.
Expanding Across International Markets
The newly secured funding will enable TidalSense to accelerate rollout of its diagnostic platform across the National Health Service following its commercial introduction.
The company also plans to expand further across European healthcare markets while preparing for entry into the United States.
Alongside commercial expansion, investment will continue supporting development of its artificial intelligence platform and broader respiratory disease portfolio.
The company sees significant opportunities to apply its technology across additional respiratory conditions beyond COPD.
Shaping the Future of Respiratory Diagnostics
Artificial intelligence is increasingly transforming medical diagnostics by enabling healthcare professionals to obtain faster and more accurate clinical insights.
TidalSense believes respiratory testing should become simpler, quicker, and more widely available without compromising clinical quality.
With fresh funding, expanding healthcare adoption, and an AI platform trained on millions of breathing samples, the company is positioning itself to modernise respiratory diagnosis. By combining advanced sensing technology with intelligent data analysis, TidalSense aims to help clinicians diagnose lung disease earlier, improve patient outcomes, and make high quality respiratory care accessible to more people around the world.
